Sunshine Biopharma (SBFM)

Executive Summary

Sunshine Biopharma Inc. (SBFM) is a Canadian pharmaceutical company developing novel oncology therapeutics. Its lead candidate is a small molecule inhibitor of P-glycoprotein, a key multi-drug resistance protein in cancer cells, which is currently in preclinical or early clinical stages. The company is also advancing an mRNA-based anticancer vaccine in collaboration with the University of Georgia. In addition to its proprietary pipeline, Sunshine Biopharma generates revenue through a portfolio of generic prescription and non-prescription drugs commercialized in Canada via its subsidiary. The company's dual strategy of internal R&D and established generic distribution provides a balanced approach to funding its clinical-stage assets. However, with a market capitalization around $5 million, Sunshine Biopharma is a micro-cap stock with high risk and limited liquidity.

Upcoming Catalysts (preview)

• Q4 2026Lead inhibitor clinical trial update25% success
• H1 2027mRNA vaccine technology milestone30% success
• TBDGeneric drug revenue growth or new product launch50% success